Glycemic Response to Metformin and Its Association with Age and Gender in Type II Diabetes: Glycemic Response to Metformin

Zunera  Hakim; Asma  Khan; Akbar  Waheed; Amtul  Hafeez; Aamna  Khohkar; Bareera  Hakim

doi:10.54393/pbmj.v5i7.691

Authors

Zunera Hakim Rawalpindi Medical University, Rawalpindi
Asma Khan Rawalpindi Medical University, Rawalpindi
Akbar Waheed Islamic International Medical College, Rawalpindi
Amtul Hafeez Islam Medical College, Sialkot
Aamna Khohkar Islamabad Medical and Dental College, Islamabad
Bareera Hakim Rafiqui Hospital Trust, Shorkot

DOI:

https://doi.org/10.54393/pbmj.v5i7.691

Keywords:

Metformin, Type –II diabetes, gender, glycemic response

Abstract

Diabetes Mellitus has become a global health concern due to its continued rise in prevalence. According to International Diabetic Federation (IDF), Type II diabetes mellitus (T2DM) currently affects 462 million people worldwide and is expected to grow from this figure to 642 million by 2040. Objective: The study was conducted to evaluate the glycemic response to metformin in Type-II diabetes and assess its association with age and gender. Methods: A cross sectional study was conducted at the Pharmacology Department of Riphah International University from Jan 2020 to Dec 2021.Type-II diabetic patients (n=200) on metformin monotherapy fulfilling the inclusion criteria were enrolled and followed up till three months. Baseline parameters were documented and reduction in HbA1c was determined. Numerical and categorical data was analyzed by chi-square and t-test using SPPS 23. Results: Our study demonstrates that 52% (104) of the patients were metformin responders while 48% (96) were non-responders. The reduction in HbA1c was significantly greater in responders than non- responders (- 1.58±1.07 % VS -0.32±0.35 %). Out of 85 males, 46 (54%) responded to metformin optimally while only half (50%) of the female subjects produced desirable response. However, there was no effect of gender on metformin response status with p=0.60 and changes in HbA1c levels over time were not significantly different in either sex. The mean age of responders and non-responders was found to be 48.23±9.64 years and 44.13±7.82 respectively. The effect of age on response of metformin and mean change in HbA1c among different age groups was found to be statistically significant with p=0.03 and p=0.04 respectively. Conclusion: There exists variability in response to metformin in type-II diabetes which is associated with age of the patient but remains un-influenced by gender of the patient.

References

Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and clinical practice. 2017 Jun; 128:40-50. doi: 10.1016/j.diabres.2017.03.024.

Aamir AH, Ul-Haq Z, Fazid S, Shah BH, Raza A, Jawa A, et al. Type 2 diabetes prevalence in Pakistan: what is driving this? Clues from subgroup analysis of normal weight individuals in diabetes prevalence survey of Pakistan. Cardiovascular Endocrinology and Metabolism 2020 Jun; 9(4):159-164. doi: 10.1097/XCE.0000000000000212.

de Vries ST, Denig P, Ekhart C, Mol PG, van Puijenbroek EP. Sex differences in adverse drug reactions of metformin: a longitudinal survey study. Drug safety. 2020 May; 43(5):489-495. doi: 10.1007/s40264-020-00913-8.

Sanchez-Ibarra HE, Reyes-Cortes LM, Jiang XL, Luna-Aguirre CM, Aguirre-Trevino D, Morales-Alvarado IA, et al. Genotypic and phenotypic factors influencing drug response in Mexican patients with type 2 diabetes mellitus. Frontiers in Pharmacology. 2018 Apr; 9:320. 2018 Apr 6; 9:320. doi: 10.3389/fphar.2018.00320.

Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014 Aug; 63(8):2590-9. doi: 10.2337/db13-1367.

Abdulrahman ZS, Alatrakji MQ, Al-Maliky AA, Hussein KI, Hussain SA. The Association of Metformin Doses and Length of Treatment with Glycemic Control and Serum Insulin Levels in Iraqi Patients with Type-2 Diabetes Mellitus. Biomedical and Pharmacology Journal. 2022 Jun; 15(2). doi.org/10.13005/bpj/2441

Ilias I, Rizzo M, Zabuliene L. Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review. Medicina (Kaunas). 2022 Mar; 58(3):430. doi: 10.3390/medicina58030430.

Schütt M, Zimmermann A, Hood R, Hummel M, Seufert J, Siegel E, et al. Gender-specific effects of treatment with lifestyle, Metformin or sulfonylurea on glycemic control and body weight: A German multicenter analysis on 9 108 patients. Experimental and Clinical Endocrinology & Diabetes. 2015 Nov; 123(10):622-6. doi: 10.1055/s-0035-1559608.

Cambra K, Galbete A, Forga L, Lecea O, Ariz MJ, Moreno-Iribas C, et al. Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. BMC family practice. 2016 Oct; 17(1):144. doi: 10.1186/s12875-016-0533-9.

General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. The Journal of the American College of Dentists. 2014; 81(3):14-8.

Raj GM, Mathaiyan J, Wyawahare M, Priyadarshini R. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients. Drug Metabolism and Personalized Therapy 2018 Dec; 33(4):175-185. doi: 10.1515/dmpt-2018-0030.

Rashid M, Shahzad M, Mahmood S, Khan K. Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. Pakistan journal of medical sciences. 2019 Feb; 35(1):71-76. doi: 10.12669/pjms.35.1.100.

Kashi Z, Mahrooz A, Kianmehr A, Alizadeh A. The role of metformin response in lipid metabolism in patients with recent-onset type 2 diabetes: HbA1c level as a criterion for designating patients as responders or nonresponders to metformin. PloS one. 2016 Mar; 11(3): e0151543. doi: 10.1371/journal.pone.0151543.

Fang HSA, Gao Q, Tan WY, Lee ML, Hsu W, Tan NC. The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study. BMC Medicine. 2022 Jan; 20(1):22. doi: 10.1186/s12916-021-02221-z.

Williams LK, Padhukasahasram B, Ahmedani BK, Peterson EL, Wells KE, González Burchard E, et al. Differing effects of metformin on glycemic control by race-ethnicity. The Journal of Clinical Endocrinology & Metabolism. 2014 Sep; 99(9):3160-8. doi: 10.1210/jc.2014-1539.

Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L, et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC medicine. 2018 Jul; 16(1):116. doi: 10.1186/s12916-018-1085-8

Mohan V, Zargar A, Chawla M, Joshi A, Ayyagari U, Sethi B, et al. Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021 Jun; 14:2925-2933. doi: 10.2147/DMSO.S315227.

G Duarte F, da Silva Moreira S, Almeida MDCC, de Souza Teles CA, Andrade CS, Reingold AL, et al. Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela. BMJ Open. 2019 Mar; 9(3): e023401. doi: 10.1136/bmjopen-2018-023401.

Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabetic medicine. 2007 Apr; 24(4):350-8. doi.org/10.1111/j.1464-5491.2007. 02078.x

Nichols GA, Conner C, Brown JB. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Current medical research and opinion. 2010 Sep; 26 (9):2127-35. doi: 10.1185/03007995.2010.504396.

Aschner P, Katzeff HL, Guo H, Sunga S, Williams‐Herman D, Kaufman KD, et al. Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2010 Mar; 12(3):252-61. doi: 10.1111/j.1463-1326.2009.01187. x.

Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabetic medicine. 2006 Feb; 23(2):128-33. doi: 10.1111/j.1464-5491.2005.01755. x.